Edition:
India

Sangamo Therapeutics Inc (SGMO.OQ)

SGMO.OQ on NASDAQ Stock Exchange Global Select Market

15.05USD
19 Jul 2018
Change (% chg)

$-0.05 (-0.33%)
Prev Close
$15.10
Open
$15.00
Day's High
$15.30
Day's Low
$14.75
Volume
419,129
Avg. Vol
501,828
52-wk High
$27.50
52-wk Low
$8.00

Latest Key Developments (Source: Significant Developments)

Sangamo Therapeutics Reports Q1 Loss Per Share Of $0.23
Tuesday, 8 May 2018 

May 8 (Reuters) - Sangamo Therapeutics Inc ::SANGAMO THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 REVENUE $12.6 MILLION VERSUS $3.4 MILLION.Q1 REVENUE VIEW $53.1 MILLION -- THOMSON REUTERS I/B/E/S.Q1 LOSS PER SHARE $0.23.Q1 EARNINGS PER SHARE VIEW $0.48 -- THOMSON REUTERS I/B/E/S.SAYS EXPECTS THAT OPERATING EXPENSES WILL BE IN RANGE OF $140 MILLION TO $150 MILLION FOR YEAR-END 2018.  Full Article

Sangamo Therapeutics Prices Public Offering Of Common Stock
Thursday, 26 Apr 2018 

April 25 (Reuters) - Sangamo Therapeutics Inc ::SANGAMO THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 12.3 MILLION COMMON SHARES PRICED AT $16.25PER SHARE.  Full Article

Sangamo And Pfizer Announce Collaboration For Development Of Zinc Finger Protein Gene Therapy For Als
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Pfizer Inc ::SANGAMO AND PFIZER ANNOUNCE COLLABORATION FOR DEVELOPMENT OF ZINC FINGER PROTEIN GENE THERAPY FOR ALS.SANGAMO THERAPEUTICS​ - CO, ‍PFIZER ANNOUNCED COLLABORATION FOR DEVELOPMENT OF ZINC FINGER PROTEIN GENE THERAPY FOR ALS.SANGAMO THERAPEUTICS INC - UNDER TERMS OF COLLABORATION AGREEMENT, SANGAMO WILL RECEIVE A $12 MILLION UPFRONT PAYMENT FROM PFIZER.SANGAMO THERAPEUTICS INC - UNDER AGREEMENT, CO ‍WILL BE RESPONSIBLE FOR DEVELOPMENT OF ZFP-TF CANDIDATES​.SANGAMO - UNDER TERMS ELIGIBLE TO RECEIVE POTENTIAL DEVELOPMENT & COMMERCIAL MILESTONE PAYMENTS UP TO $150 MILLION, TIERED ROYALTIES ON NET SALES.SANGAMO - UNDER DEAL,‍PFIZER OPERATIONALLY,FINANCIALLY RESPONSIBLE FOR RESEARCH,DEVELOPMENT,COMMERCIALIZATION FOR C9ORF72 ZFP-TF,RESULTING PRODUCTS.  Full Article

Sangamo Says European Medicines Agency Recommends Orphan Medicinal Product Designation For Investigational Genome Editing Treatments
Friday, 8 Dec 2017 

Dec 7 (Reuters) - Sangamo Therapeutics Inc ::SANGAMO ANNOUNCES EUROPEAN MEDICINES AGENCY RECOMMENDATION OF ORPHAN MEDICINAL PRODUCT DESIGNATION FOR INVESTIGATIONAL GENOME EDITING TREATMENTS FOR MPS I AND MPS II.SANGAMO THERAPEUTICS - PHASE 1/2 CLINICAL TRIALS FOR PROGRAMS, EVALUATING SB-318 & SB-913 IN ADULTS WITH MPS I AND MPS II, ARE ENROLLING SUBJECTS.  Full Article

Sangamo says patient received therapy intended to precisely edit DNA of cells directly inside body​
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Sangamo Therapeutics Inc -:Sangamo announces treatment of first patient in landmark phase 1/2 clinical trial evaluating in vivo genome editing for MPS II.‍A patient has received a therapy intended to precisely edit DNA of cells directly inside body​.  Full Article

Sangamo Therapeutics posts Q3 loss per share $0.15
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Sangamo Therapeutics Inc :Sangamo Therapeutics reports third quarter 2017 financial results.Q3 revenue $11.8 million versus I/B/E/S view $10.4 million.Q3 loss per share $0.15.Sees FY 2017 revenue $30 million to $40 million.Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.Sangamo Therapeutics Inc - ‍company expects that revenues will be in range of $30 million to $40 million in 2017​.FY2017 revenue view $33.2 million -- Thomson Reuters I/B/E/S.  Full Article

Sangamo Biosciences receives orphan drug designation from the FDA for sb-fix, the first application of therapeutic in vivo genome editing
Tuesday, 6 Sep 2016 

Sangamo Biosciences Inc : Fix, the first application of therapeutic in vivo genome editing .Sangamo Biosciences Inc Says Expects To Initiate A Phase 1/2 Clinical Study (Sb fix-1501) in adult subjects with disease in 2016.  Full Article

Sangamo Bio sees FY 2016 revenue $12 million to $17 million
Thursday, 4 Aug 2016 

Sangamo Biosciences Inc : Sangamo biosciences reports second quarter 2016 financial results . Q2 revenue view $5.4 million -- Thomson Reuters I/B/E/S . Sees fy 2016 revenue $12 million to $17 million . Q2 revenue $3.7 million versus $8.4 million . Q2 loss per share $0.38 . Q2 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S .Sangamo expects that operating expenses will be in range of $85 million to $95 million for 2016.  Full Article